Therapeutic hypothermia and the risk of hemorrhage: A systematic review and meta-analysis of randomized controlled trials

Chih Hung Wang, Nai Chuan Chen, Min Shan Tsai, Ping Hsun Yu, An Yi Wang, Wei Tien Chang, Chien Hua Huang, Wen Jone Chen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Current guidelines recommend a period of moderate therapeutic hypothermia (TH) for comatose patients after cardiac arrest to improve clinical outcomes. However, in-vitro studies have reported platelet dysfunction, thrombocytopenia, and coagulopathy, results that might discourage clinicians from applying TH in clinical practice. We aimed to quantify the risks of hemorrhage observed in clinical studies. Medline and Embase were searched from inception to October 2015. Randomized controlled trials (RCTs) comparing patients undergoing TH with controls were selected, irrespective of the indications for TH. There were no restrictions for language, population, or publication year. Data on study characteristics, which included patients, details of intervention, and outcome measures, were extracted. Forty-three trials that included 7528 patients were identified from 2692 potentially relevant references. Any hemorrhage was designated as the primary outcome and was reported in 28 studies. The pooled results showed no significant increase in hemorrhage risk associated with TH (risk difference [RD] 0.005; 95% confidence interval [CI]-0.001- 0.011; I2, 0%). Among secondary outcomes, patients undergoing TH were found to have increased risk of thrombocytopenia (RD 0.109; 95% CI 0.038-0.179; I2 57.3%) and transfusion requirements (RD 0.021; 95% CI 0.003-0.040; I2 0%). The meta-regression analysis indicated that prolonged duration of cooling may be associated with increased risk of hemorrhage. TH was not associated with increased risk of hemorrhage despite the increased risk of thrombocytopenia and transfusion requirements. Clinicians should cautiously assess each patient's risk-benefit profile before applying TH.

Original languageEnglish
Pages (from-to)e2152
JournalMedicine (United States)
Volume94
Issue number47
DOIs
Publication statusPublished - Nov 1 2015
Externally publishedYes

Fingerprint

Induced Hypothermia
Meta-Analysis
Randomized Controlled Trials
Hemorrhage
Thrombocytopenia
Confidence Intervals
Coma
Heart Arrest
Publications
Language
Blood Platelets
Regression Analysis
Outcome Assessment (Health Care)
Guidelines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic hypothermia and the risk of hemorrhage : A systematic review and meta-analysis of randomized controlled trials. / Wang, Chih Hung; Chen, Nai Chuan; Tsai, Min Shan; Yu, Ping Hsun; Wang, An Yi; Chang, Wei Tien; Huang, Chien Hua; Chen, Wen Jone.

In: Medicine (United States), Vol. 94, No. 47, 01.11.2015, p. e2152.

Research output: Contribution to journalArticle

Wang, Chih Hung ; Chen, Nai Chuan ; Tsai, Min Shan ; Yu, Ping Hsun ; Wang, An Yi ; Chang, Wei Tien ; Huang, Chien Hua ; Chen, Wen Jone. / Therapeutic hypothermia and the risk of hemorrhage : A systematic review and meta-analysis of randomized controlled trials. In: Medicine (United States). 2015 ; Vol. 94, No. 47. pp. e2152.
@article{07dd11afc3fe492b84b41c5d0017e6bd,
title = "Therapeutic hypothermia and the risk of hemorrhage: A systematic review and meta-analysis of randomized controlled trials",
abstract = "Current guidelines recommend a period of moderate therapeutic hypothermia (TH) for comatose patients after cardiac arrest to improve clinical outcomes. However, in-vitro studies have reported platelet dysfunction, thrombocytopenia, and coagulopathy, results that might discourage clinicians from applying TH in clinical practice. We aimed to quantify the risks of hemorrhage observed in clinical studies. Medline and Embase were searched from inception to October 2015. Randomized controlled trials (RCTs) comparing patients undergoing TH with controls were selected, irrespective of the indications for TH. There were no restrictions for language, population, or publication year. Data on study characteristics, which included patients, details of intervention, and outcome measures, were extracted. Forty-three trials that included 7528 patients were identified from 2692 potentially relevant references. Any hemorrhage was designated as the primary outcome and was reported in 28 studies. The pooled results showed no significant increase in hemorrhage risk associated with TH (risk difference [RD] 0.005; 95{\%} confidence interval [CI]-0.001- 0.011; I2, 0{\%}). Among secondary outcomes, patients undergoing TH were found to have increased risk of thrombocytopenia (RD 0.109; 95{\%} CI 0.038-0.179; I2 57.3{\%}) and transfusion requirements (RD 0.021; 95{\%} CI 0.003-0.040; I2 0{\%}). The meta-regression analysis indicated that prolonged duration of cooling may be associated with increased risk of hemorrhage. TH was not associated with increased risk of hemorrhage despite the increased risk of thrombocytopenia and transfusion requirements. Clinicians should cautiously assess each patient's risk-benefit profile before applying TH.",
author = "Wang, {Chih Hung} and Chen, {Nai Chuan} and Tsai, {Min Shan} and Yu, {Ping Hsun} and Wang, {An Yi} and Chang, {Wei Tien} and Huang, {Chien Hua} and Chen, {Wen Jone}",
year = "2015",
month = "11",
day = "1",
doi = "10.1097/MD.0000000000002152",
language = "English",
volume = "94",
pages = "e2152",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "47",

}

TY - JOUR

T1 - Therapeutic hypothermia and the risk of hemorrhage

T2 - A systematic review and meta-analysis of randomized controlled trials

AU - Wang, Chih Hung

AU - Chen, Nai Chuan

AU - Tsai, Min Shan

AU - Yu, Ping Hsun

AU - Wang, An Yi

AU - Chang, Wei Tien

AU - Huang, Chien Hua

AU - Chen, Wen Jone

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Current guidelines recommend a period of moderate therapeutic hypothermia (TH) for comatose patients after cardiac arrest to improve clinical outcomes. However, in-vitro studies have reported platelet dysfunction, thrombocytopenia, and coagulopathy, results that might discourage clinicians from applying TH in clinical practice. We aimed to quantify the risks of hemorrhage observed in clinical studies. Medline and Embase were searched from inception to October 2015. Randomized controlled trials (RCTs) comparing patients undergoing TH with controls were selected, irrespective of the indications for TH. There were no restrictions for language, population, or publication year. Data on study characteristics, which included patients, details of intervention, and outcome measures, were extracted. Forty-three trials that included 7528 patients were identified from 2692 potentially relevant references. Any hemorrhage was designated as the primary outcome and was reported in 28 studies. The pooled results showed no significant increase in hemorrhage risk associated with TH (risk difference [RD] 0.005; 95% confidence interval [CI]-0.001- 0.011; I2, 0%). Among secondary outcomes, patients undergoing TH were found to have increased risk of thrombocytopenia (RD 0.109; 95% CI 0.038-0.179; I2 57.3%) and transfusion requirements (RD 0.021; 95% CI 0.003-0.040; I2 0%). The meta-regression analysis indicated that prolonged duration of cooling may be associated with increased risk of hemorrhage. TH was not associated with increased risk of hemorrhage despite the increased risk of thrombocytopenia and transfusion requirements. Clinicians should cautiously assess each patient's risk-benefit profile before applying TH.

AB - Current guidelines recommend a period of moderate therapeutic hypothermia (TH) for comatose patients after cardiac arrest to improve clinical outcomes. However, in-vitro studies have reported platelet dysfunction, thrombocytopenia, and coagulopathy, results that might discourage clinicians from applying TH in clinical practice. We aimed to quantify the risks of hemorrhage observed in clinical studies. Medline and Embase were searched from inception to October 2015. Randomized controlled trials (RCTs) comparing patients undergoing TH with controls were selected, irrespective of the indications for TH. There were no restrictions for language, population, or publication year. Data on study characteristics, which included patients, details of intervention, and outcome measures, were extracted. Forty-three trials that included 7528 patients were identified from 2692 potentially relevant references. Any hemorrhage was designated as the primary outcome and was reported in 28 studies. The pooled results showed no significant increase in hemorrhage risk associated with TH (risk difference [RD] 0.005; 95% confidence interval [CI]-0.001- 0.011; I2, 0%). Among secondary outcomes, patients undergoing TH were found to have increased risk of thrombocytopenia (RD 0.109; 95% CI 0.038-0.179; I2 57.3%) and transfusion requirements (RD 0.021; 95% CI 0.003-0.040; I2 0%). The meta-regression analysis indicated that prolonged duration of cooling may be associated with increased risk of hemorrhage. TH was not associated with increased risk of hemorrhage despite the increased risk of thrombocytopenia and transfusion requirements. Clinicians should cautiously assess each patient's risk-benefit profile before applying TH.

UR - http://www.scopus.com/inward/record.url?scp=84983503485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983503485&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002152

DO - 10.1097/MD.0000000000002152

M3 - Article

C2 - 26632746

AN - SCOPUS:84983503485

VL - 94

SP - e2152

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 47

ER -